Linezolid resistance in Staphylococcus aureus: Characterization and stability of resistant phenotype

Journal of Infectious Diseases

Volumn 186, Issue 11, 2002, Pages 1603-1607

  Pillai, Satish K ^c,d   Sakoulas, George ^a,c   Wennersten, Christine ^a   Eliopoulos, George M ^a,c   Moellering Jr , Robert C ^a,c   Ferraro, Mary Jane ^b,c   Gold, Howard S ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM; GLYCOPEPTIDE; LINEZOLID; METICILLIN; RIBOSOME RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; GENETIC STABILITY; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DNA, RIBOSOMAL; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; OXAZOLIDINONES; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS AUREUS;

EID: 0036890601     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345368     Document Type: Article

References (19)

1. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29:404-21.
2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358:1975-82.
3. Aoki H, Ke L, Poppe SM, et al. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002; 46:1080-5.
4. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93-101.
5. Shinabarger DL. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 1999; 8:1195-202.
6. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40:799-801.
7. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL, Zurenko GE. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA [abstract C-104]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, 1998). Washington, DC: American Society of Microbiology, 1998:98-9.
8. Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, 1999). Washington, DC: American Society of Microbiology, 1999:118.
9. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
10. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357:1225-40.
11. Schaefler S, Perry W, Jones D. Methicillin-resistant strains of Staphylococcus aureus phage type 92. Antimicrob Agents Chemother 1979; 15:74-80.
12. Pitcher DG, Saunders NA, Owen RJ. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett Appl Microbiol 1989; 8:151-6.
13. Ausubel FM, Brent R, Kingston RE, et al. Short Protocols in Molecular Biology. 3rd Ed. New York: John Wiley & Sons, 1997.
14. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154-6.
15. Xiong L, Kloss P, Douthwaite S, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000; 182:5325-31.
16. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346:867-9.
17. Goering RV, Black T, Hare R, Nolling J, A comparison of ribosomal RNA operon distribution in methicillin-resistant Staphylococcus aureus (MRSA) strains currently in genomic sequence analysis [abstract C2-300]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, 2001). Washington, DC: American Society of Microbiology, 2001:119.
18. Wada A, Ohta H, Kulthanan K, Hiramatsu K. Molecular cloning and mapping of 16S-23S rRNA gene complexes of Staphylococcus aureus. J Bacteriol 1993; 175:7483-7.
19. Murray RW, Schaadt RD, Zurenko GE, Marotti KR. Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay. Antimicrob Agents Chemother 1998; 42:947-50.